IFP Advisors Inc Acquires 179 Shares of Zoetis Inc. (NYSE:ZTS)

IFP Advisors Inc increased its holdings in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 2.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,677 shares of the company’s stock after purchasing an additional 179 shares during the period. IFP Advisors Inc’s holdings in Zoetis were worth $1,515,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. State Street Corp increased its position in shares of Zoetis by 1.1% during the 2nd quarter. State Street Corp now owns 19,630,557 shares of the company’s stock worth $3,380,578,000 after purchasing an additional 213,907 shares during the last quarter. Capital International Investors raised its stake in Zoetis by 1.1% in the 2nd quarter. Capital International Investors now owns 15,262,031 shares of the company’s stock valued at $2,628,251,000 after acquiring an additional 167,641 shares during the period. Wellington Management Group LLP raised its stake in Zoetis by 2.5% in the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after acquiring an additional 297,044 shares during the period. Morgan Stanley increased its position in Zoetis by 34.6% during the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock worth $1,593,395,000 after buying an additional 2,796,694 shares during the period. Finally, Geode Capital Management LLC increased its position in Zoetis by 3.0% during the 2nd quarter. Geode Capital Management LLC now owns 10,031,189 shares of the company’s stock worth $1,723,104,000 after buying an additional 291,819 shares during the period. Institutional investors own 89.47% of the company’s stock.

Zoetis Price Performance

ZTS opened at $170.67 on Tuesday. The stock has a 50-day moving average price of $189.72 and a 200-day moving average price of $183.19. Zoetis Inc. has a 12-month low of $151.03 and a 12-month high of $201.92. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $78.14 billion, a P/E ratio of 33.66, a PEG ratio of 2.63 and a beta of 0.87.

Zoetis (NYSE:ZTSGet Free Report) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the prior year, the company earned $1.15 earnings per share. The company’s revenue was up 8.5% compared to the same quarter last year. Equities analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.01%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the sale, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 2,209 shares of company stock worth $408,453. Corporate insiders own 0.15% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ZTS shares. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Barclays raised their price objective on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. Stifel Nicolaus raised their price objective on Zoetis from $195.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, January 12th. Piper Sandler raised their price objective on Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group raised their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus price target of $224.33.

Check Out Our Latest Research Report on ZTS

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.